Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Toxicol In Vitro ; 30(1 Pt B): 309-17, 2015 Dec 25.
Artigo em Inglês | MEDLINE | ID: mdl-26475966

RESUMO

Apoptosis and NETosis of neutrophils are two major mechanisms of programmed cell death that differ in their morphological characteristics and effects on the immune system. Apoptosis can be delayed by the presence of pathogens or chemical components such as lipopolysaccharide (LPS). Neutrophils have other antimicrobial strategy, called neutrophil extracellular traps (NETs), which contributes to the elimination and control of the pathogen. NETosis is induced by infection, inflammation or trauma and represents an innate immune activation mechanism. The objective of this study was to evaluate the effect of gallic acid (GA) in the modulation of apoptosis and NETs release. The results show that GA decreased the anti-apoptotic effect of LPS, blocked the induction of NETs and prevented the formation of free radicals induced by LPS. These findings demonstrate that the GA is a novel therapeutic agent for decreasing the exacerbated response of the body against an infectious agent.


Assuntos
Apoptose/efeitos dos fármacos , Armadilhas Extracelulares/efeitos dos fármacos , Ácido Gálico/farmacologia , Lipopolissacarídeos/toxicidade , Neutrófilos/efeitos dos fármacos , Caspase 3/metabolismo , Citocinas/metabolismo , Humanos
2.
Cell Biol Int ; 38(4): 526-30, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24353036

RESUMO

(+)-Catechin is a type of catechin present in large amounts in açaí fruits and cocoa seeds. Besides its antioxidant and anti-inflammatory activities, little is known about its effects in the liver, especially during hepatic fibrosis. We report here the effects of (+)-catechin on hepatic stellate cells. (+)-Catechin induced quiescent phenotype in GRX cells, along with an increase in lipid droplets. Proliferator-activated receptor γ mRNA expression was upregulated, whereas type I collagen mRNA expression was downregulated. Pro-inflammatory cytokines were not influenced by (+)-catechin, whereas the levels of interleukin 10 were significantly increased. The data provide evidence that (+)-catechin can reduce hepatic stellate cell activation.


Assuntos
Catequina/farmacologia , Células Estreladas do Fígado/efeitos dos fármacos , Animais , Linhagem Celular , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Citocinas/metabolismo , Regulação para Baixo/efeitos dos fármacos , Células Estreladas do Fígado/citologia , Interleucina-10/metabolismo , Lipídeos/biossíntese , Camundongos , PPAR gama/genética , PPAR gama/metabolismo , RNA Mensageiro/metabolismo , Estereoisomerismo , Regulação para Cima/efeitos dos fármacos
3.
Eur J Pharmacol ; 720(1-3): 320-5, 2013 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-24144957

RESUMO

Hepatic stellate cells (HSC) play a key role in liver fibrogenesis. Activation of PPARγ and inhibition of fibrogenic molecules are potential strategies to block HSC activation and differentiation. Aware that the process of hepatic fibrosis involves inflammatory mediators, various anti-inflammatory substances have been studied in an attempt to revert fibrosis. The purpose of this study was to investigate the in vitro effects of fructose-1,6-bisphosphate (FBP) on HSC phenotype reversion. The results demonstrated that FBP induced quiescent phenotype in GRX cells via PPARγ activation. Significant decrease in type I collagen mRNA expression was observed in the first 24h of treatment. These events preceded the reduction of TGF-ß1 and total collagen secretion. Thus, FBP promoted downregulation of HSC activation by its antifibrotic action. These findings demonstrate that FBP may have potential as a novel therapeutic agent for the treatment of liver fibrosis.


Assuntos
Frutosedifosfatos/farmacologia , Células Estreladas do Fígado/efeitos dos fármacos , PPAR gama/genética , Animais , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Colágeno/genética , Colágeno/metabolismo , Fibrose/tratamento farmacológico , Células Estreladas do Fígado/metabolismo , Metabolismo dos Lipídeos/efeitos dos fármacos , Camundongos , RNA Mensageiro/metabolismo , Fator de Crescimento Transformador beta/metabolismo
4.
Biochem Cell Biol ; 90(6): 683-90, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22905849

RESUMO

Hepatic stellate cells (HSC) play a key role in liver fibrogenesis. Activation of PPARγ and inhibition of fibrogenic molecules are potential strategies to block HSC activation and differentiation. A number of natural products have been suggested to have antifibrotic effects for the de-activation and de-differentiation of HSCs. The purpose of this study was to investigate the in vitro effects of capsaicin on HSC de-activation and de-differentiation. The results demonstrated that capsaicin induced quiescent phenotype in GRX via PPARγ activation. Significant decrease in COX-2 and type I collagen mRNA expression was observed in the first 24 h of treatment. These events preceded the reduction of TGF-ß1 and total collagen secretion. Thus, capsaicin promoted down-regulation of HSC activation by its antifibrotic and anti-inflammatory actions. These findings demonstrate that capsaicin may have potential as a novel therapeutic agent for the treatment of liver fibrosis.


Assuntos
Capsaicina/farmacologia , Diferenciação Celular , Células Estreladas do Fígado/citologia , Animais , Anti-Inflamatórios/farmacologia , Células Cultivadas , Ciclo-Oxigenase 2/genética , Ciclo-Oxigenase 2/metabolismo , Regulação para Baixo , Células Estreladas do Fígado/efeitos dos fármacos , Células Estreladas do Fígado/metabolismo , PPAR gama/genética , PPAR gama/metabolismo , Fator de Crescimento Transformador beta1/metabolismo
5.
J. bras. patol. med. lab ; 48(2): 109-115, abr. 2012. tab
Artigo em Inglês | LILACS | ID: lil-623369

RESUMO

INTRODUCTION: Sepsis is a complex syndrome caused by an uncontrolled systemic inflammatory response. Inflammatory cytokines play a pivotal role in septic shock pathogenesis. Therapeutic strategies have been tested in order to modulate the excessive generation or function of sepsis mediators. OBJECTIVE: The objective of the present study was to investigate the therapeutic effect of N-acetylcysteine (NAC) and its association with fructose-1,6-bisphosphate (FBP) on T-lymphocytes proliferation, interleukin-1β (IL-1β) and monocyte chemotactic protein-1 (MCP-1) levels. MATERIAL AND METHODS: Peripheral blood mononuclear cell samples were isolated from healthy individuals. T-lymphocytes were stimulated with phytohemagglutinin for 96 hours and submitted to different concentrations of NAC or NAC associated with FBP. RESULTS: NAC (10 and 15 mM) and NAC (15 mM) associated with FBP reduced T-lymphocytes proliferation. IL-1β levels rose in the presence of both NAC (15 mM) and NAC with FBP (1.25 mM). MCP-1 levels were reduced only by NAC (15 mM) associated with FBP (1.25 mM). CONCLUSION: The results suggest that both NAC itself and NAC associated with FBP inhibit cellular proliferation, acting as potent immunomodulatory agents, which corroborates its use in the treatment of inflammatory diseases.


INTRODUÇÃO: A sepse é uma síndrome complexa causada pela resposta inflamatória sistêmica descontrolada. As citocinas inflamatórias representam papel central na patogênese do choque séptico. Têm sido testadas estratégias terapêuticas a fim de modular a geração ou a função excessiva de mediadores na sepse. OBJETIVO: O objetivo deste estudo foi investigar o efeito terapêutico da N-acetilcisteína (NAC) e sua associação com a frutose-1,6-bisfosfato (FBP) sobre a proliferação de linfócitos T e a geração de interleucina-1β (IL-1β) e proteína quimiotática de monócitos 1 (MCP-1) em cultura celular. MATERIAL E MÉTODOS: Foram isoladas células mononucleares de sangue periférico de indivíduos saudáveis. Os linfócitos T foram estimulados por 96 horas com fitohemaglutinina e submetidos a diferentes concentrações de NAC ou NAC associada à FBP (1,25 mM). RESULTADOS: O tratamento com NAC (10 e 15 mM) ou NAC (15 mM) associado à FBP reduziu a proliferação celular. Os níveis de IL-1β aumentaram com a presença de NAC (15 mM) e NAC + FBP. A concentração de MCP-1 mostrou-se reduzida apenas no grupo tratado com NAC associada à FBP. CONCLUSÃO: Os resultados sugerem que tanto a NAC quanto a NAC associada à FBP são capazes de inibir a proliferação celular, atuando como potentes agentes imunomoduladores, sugerindo seu uso em doenças inflamatórias.


Assuntos
Humanos , Acetilcisteína/uso terapêutico , Frutose-Bifosfatase/uso terapêutico , Interleucina-1beta , Linfócitos T , Proliferação de Células , Sepse/tratamento farmacológico
6.
J. bras. patol. med. lab ; 47(1): 43-48, fev. 2011. graf, tab
Artigo em Inglês | LILACS | ID: lil-578759

RESUMO

INTRODUCTION AND OBJECTIVE: It has been suggested that type 2 diabetes is an inflammatory response manifestation. The main drugs used to treat type 2 diabetes are sulphonylureas and biguanides. The aim of this study was to demonstrate the modulatory effects of oral hypoglycemic drugs (chlorpropamide and metformin) on lymphocyte proliferation in vitro and ex vivo. METHODS: Peripheral blood mononuclear cells were isolated from human blood by gradient centrifugation. T-lymphocytes were stimulated by phytohemagglutinin (PHA) and oral hypoglycemic drugs. RESULTS: In both in vitro and ex vivo experiments, there was a reduction in cell proliferation after treatment with oral hypoglycemic drugs. When both drugs were used in combination, a high level of cytotoxicity was observed, which made analysis of immunomodulatory effects unfeasible. DISCUSSION AND CONCLUSION: We demonstrated that diabetes itself may reduce cell proliferation significantly when stimulated by PHA, which may indicate that diabetic patients have difficulties in promoting an efficient inflammatory response. Moreover, the use of oral hypoglycemic drugs may aggravate this situation.


INTRODUÇÃO E OBJETIVOS: Tem sido sugerido que o diabetes mellitus tipo 2 (DM2) é uma manifestação da resposta inflamatória. As principais drogas utilizadas no tratamento do DM2 são as sulfonilureias e as biguanidas. O objetivo deste trabalho é demonstrar os efeitos moduladores na proliferação de linfócitos causada pelos hipoglicemiantes orais (clorpropamida e metformina), in vitro e ex vivo. MÉTODOS: Células mononucleares de sangue periférico foram isoladas de seres humanos por gradiente de centrifugação. Os linfócitos T foram estimulados com fito-hemaglutinina (PHA) e hipoglicemiantes. RESULTADOS: Nos experimentos in vitro e ex vivo, mostramos a redução da proliferação celular quando do tratamento com drogas hipoglicemiantes orais. Quando as drogas foram utilizadas em combinação, foi observado alto grau de citotoxicidade, tornando inviável a análise do efeito imunomodulador. DISCUSSÃO E CONCLUSÃO: Mostramos que o diabetes, por si, pode reduzir significativamente a proliferação celular quando estimulada por PHA, o que pode indicar que o paciente diabético tem dificuldade em promover a eficiente resposta inflamatória e que o uso de hipoglicemiantes pode piorar esta situação.


Assuntos
Humanos , Clorpropamida/farmacologia , Fatores Imunológicos/farmacologia , Imunomodulação , Metformina/farmacologia
7.
Inflammation ; 34(6): 539-50, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20882329

RESUMO

Sepsis is a syndrome caused by uncontrolled systemic inflammatory response of the individual, which represents a serious epidemiological problem worldwide. The aim of this study was to investigate the effect of N-acetylcysteine (NAC) and fructose-1,6-bisphosphate (FBP) in the treatment of experimental sepsis. We used rats that were divided into five experimental groups: normal control (not induced), septic control (induced using a capsule with non sterile fecal content and Escherichia coli), treated with FBP (500 mg/kg i.p.), treated with NAC (150 mg/kg i.p.), and treated with the combination of FBP with NAC. In the group treated with NAC, 16.68% of the mice survived, the FBP reduced the mortality of mice during the acute stage of the disease and increased the animals' survival time in 33.34%, and the combination of drugs had no effect. Our results show that NAC prevented the mortality of animals after septic induction. These data confirm the validity of the use of NAC in the treatment of sepsis. Our data also show that the synergistic action with FBP does not improve the picture.


Assuntos
Acetilcisteína/uso terapêutico , Frutose-Bifosfatase/uso terapêutico , Sepse/tratamento farmacológico , Acetilcisteína/farmacologia , Animais , Sinergismo Farmacológico , Quimioterapia Combinada , Frutose-Bifosfatase/farmacologia , Ratos , Sepse/mortalidade , Taxa de Sobrevida , Resultado do Tratamento
8.
Inflammopharmacology ; 19(3): 145-53, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20981574

RESUMO

RDV-8 [C(18)H(22)N(2)O(2)S (ethyl 1-butyl-6-methyl-2-phenyl-4-thioxo-1,4-dihydropyrimidine-5-carboxylate)] is derived from the 4-thioxopyrimidine, and presents important clinical effects. The present study explored the RDV-8 effects in the proliferation of human peripheral blood mononuclear cells (PBMCs), as well as in a pleurisy-induced rat model. PBMCs were directly plated in four different RDV-8 concentrations (0.0125, 0.025, 0.05 and 0.1 mg/mL). RDV-8 decreased cell proliferation and monocyte chemotactic protein 1 synthesis. The interleukin 1 levels and the cytotoxic effect were not significantly affected by RDV-8 treatment. In the carrageenan-induced pleurisy model, the RDV-8 (3 mg/kg) treatment induced a significant reduction in the exudate volume, in the polymorphonuclear leukocyte migration and in the pleural exudate NO levels. The results indicate that RDV-8 may have an immunomodulatory effect, as well as anti-inflammatory actions suggesting that it could represent a new strategy in the inflammatory response modulation.


Assuntos
Anti-Inflamatórios/farmacologia , Fatores Imunológicos/farmacologia , Pleurisia/tratamento farmacológico , Pirimidinas/farmacologia , Tionas/farmacologia , Animais , Anti-Inflamatórios/administração & dosagem , Carragenina , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Quimiocina CCL2/biossíntese , Quimiocina CCL2/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Feminino , Humanos , Fatores Imunológicos/administração & dosagem , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/metabolismo , Neutrófilos/efeitos dos fármacos , Neutrófilos/metabolismo , Óxido Nítrico/metabolismo , Pleurisia/fisiopatologia , Pirimidinas/administração & dosagem , Ratos , Ratos Wistar , Tionas/administração & dosagem
9.
Inflammation ; 33(3): 173-9, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20020191

RESUMO

The following study aimed to evaluate, in vitro and in vivo, the anti-inflammatory effect of Ulomoides dermestoides, a beetle commonly used as a remedy for a variety of diseases including respiratory disorders and asthma. We used an acute inflammation model of injury, injection of carrageenan into the pleural cavity of rats. The rats were treated intraperitoneally with the aqueous extract of U. dermestoides 8 and 16 mg/kg. The exudate volume, protein concentration, polymorphonuclear leukocytes (PMNs) and total leukocyte were measured. The peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy subjects and we investigated the immunomodulatory and cytotoxic effect of aqueous extract of U. dermestoides. In conclusion, in vitro we observed a non-cytotoxic effect and antiproliferative activity on the dose of 12.5 mg/dL. In vivo, this paper clarifies the great clinical relevance of the aqueous extract of U. dermestoides in elucidating its role as an anti-inflammatory agent.


Assuntos
Anti-Inflamatórios/farmacologia , Besouros , Proteínas de Insetos/farmacologia , Pleurisia/tratamento farmacológico , Pleurisia/imunologia , Animais , Brasil , Carragenina/toxicidade , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/imunologia , Células Cultivadas , Misturas Complexas/farmacologia , Relação Dose-Resposta a Droga , Exsudatos e Transudatos/imunologia , Feminino , Proteínas de Insetos/imunologia , Medicina Tradicional , Pleurisia/induzido quimicamente , Ratos , Ratos Wistar , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia
10.
Inflammation ; 32(6): 419-25, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19756999

RESUMO

Baccharis trimera is a widespread South American plant known as "carqueja". Medicinal teas prepared from the aerial parts of this plant are used in folk medicine in cases of liver diseases and inflammatory processes. We evaluated the effects of aqueous extract of B. trimera in the experimental inflammatory model of carrageenan-induced pleurisy in rat. The injection of carrageenan into the pleural cavity induces an influx of cells and fluid accumulation with a large number of polymorphonuclear leukocytes and increase of protein levels. The inflammation parameters were attenuated when B. trimera (400 and 800 mg/kg, i.p.) was administrated 30 min before the carrageenan. The immunomodulatory effects were evaluated in vitro on human peripheral blood mononuclear cells. The extract in concentration of 25, 50 and 100 mg/mL presented inhibited the T-lymphocytes proliferation stimulated by phytohemagglutinin, but these extract concentrations also presented cytotoxic effect. These results showed that the aqueous extract of B. trimera has anti-inflammatory effect.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Baccharis , Fatores Imunológicos/uso terapêutico , Ativação Linfocitária/imunologia , Extratos Vegetais/uso terapêutico , Pleurisia/tratamento farmacológico , Pleurisia/patologia , Linfócitos T/imunologia , Animais , Anti-Inflamatórios não Esteroides/isolamento & purificação , Anti-Inflamatórios não Esteroides/farmacologia , Baccharis/imunologia , Carragenina/toxicidade , Proliferação de Células/efeitos dos fármacos , Feminino , Humanos , Fatores Imunológicos/isolamento & purificação , Fatores Imunológicos/farmacologia , Fitoterapia/métodos , Componentes Aéreos da Planta , Extratos Vegetais/isolamento & purificação , Pleurisia/microbiologia , Ratos , Ratos Wistar , Linfócitos T/metabolismo , Água
11.
Lasers Surg Med ; 40(7): 500-8, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18727002

RESUMO

BACKGROUND AND OBJECTIVE: In the classic model of pleurisy there is little evidence about the anti-inflammatory effects of low-level laser therapy (LLLT) as well the dosage characteristics, such as wavelength, total energy, number and pattern of treatment. In this study we investigated the potential effects of LLLT on modulating the pro-inflammatory and anti-inflammatory mediators of acute inflammation in a rat pleurisy model. STUDY DESIGN/MATERIALS AND METHODS: A sample of 48 female Wistar rats were divided into control and experiential groups. An inflammation was induced by carrageenan (0.2 ml) injected into the pleural cavity. At 1, 2, and 3 hours after induction a continuous wave (20 mW) diode laser of the InGaAlP (660 nm) type was used in the four laser groups with different doses and treatment patterns. One group received a single dose of 2.1 J and the other three groups received a total energy of 0.9, 2.1, and 4.2 J. Four hours later the exudate volume, total and differential leukocytes, protein concentration, NO, IL-6, IL-10, TNF-alpha, and MCP-1 were measured from the aspirated liquid. RESULTS: All the treatment patterns and quantity of energy studied show significant reduction of the exudate volume (P<0.05). Using energy of 0.9 J only NO, IL-6, MCP-1 and IL-10 are significantly reduced (P<0.05). On the other hand, higher energies (2.1 and 4.2 J) significantly reduce all variables independently of the treatment pattern. The neutrophil migration has a straight correlation with the TNF-alpha (r = 0.551) and NO (r = 0.549) concentration. CONCLUSIONS: LLLT-660 nm induced an anti-inflammatory effect characterized by inhibition of either total or differential leukocyte influx, exudation, total protein, NO, IL-6, MCP-1, IL-10, and TNF-alpha, in a dose-dependent manner. Under these conditions, laser treatment with 2.1 J was more effective than 0.9 and 4.2 J.


Assuntos
Terapia com Luz de Baixa Intensidade , Pleurisia/radioterapia , Animais , Carragenina/administração & dosagem , Feminino , Inflamação/complicações , Inflamação/radioterapia , Pleurisia/induzido quimicamente , Pleurisia/complicações , Ratos , Ratos Wistar
12.
Pharmacol Res ; 49(5): 449-53, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-14998554

RESUMO

Inflammatory cytokines are central to the pathogenesis of septic shock, and future therapies will depend on interfering with the effects of these cytokines. The aim of this study was to investigate the effect of the two drugs, Fructose-1,6-bisphosphate (FBP), a high-energy glycolytic pathway intermediate, and chlorpropamide (sulfonylurea) on proliferation of T-lymphocytes and on the levels of soluble receptors of tumor necrosis factor (sTNFRII). Peripheral blood mononuclear cells (PMBCs) were isolated from the blood of healthy humans by gradient centrifugation. T-lymphocytes were stimulated for 96h with phytohemagglutinin (PHA) and varying concentrations of chlorpropamide and FBP. They were stimulated for 24h with lipopolysaccharide (LPS) and varying concentrations of chlorpropamide and FBP were used. Chlorpropamide at concentrations between 2.5 and 10mM and FBP at concentrations between 1.25 and 10mM decreased proliferation of T-lymphocytes. The chlorpropamide reduced the viability only at a concentration of 10mM and FBP at concentrations of 5.0 and 10mM. The levels of sTNFRII were reduced at chlorpropamide concentrations between 2.5 and 5mM and FBP between 1.25 and 2.5mM. In conclusion, our results suggest that FBP acts, as does chlorpropamide, to inhibit the cellular proliferation and thereby reducing the sTNFRII levels through blockage of the potassium channels. In this way it acts as a powerful immunomodulatory agent.


Assuntos
Clorpropamida/efeitos adversos , Frutosedifosfatos/efeitos adversos , Fatores Imunológicos/farmacologia , Receptores Tipo II do Fator de Necrose Tumoral/antagonistas & inibidores , Receptores Tipo II do Fator de Necrose Tumoral/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/imunologia , Clorpropamida/imunologia , Relação Dose-Resposta a Droga , Frutosedifosfatos/imunologia , Humanos , Leucócitos Mononucleares/citologia , Leucócitos Mononucleares/efeitos dos fármacos , Ativação Linfocitária/efeitos dos fármacos , Ativação Linfocitária/imunologia , Fito-Hemaglutininas/imunologia , Fito-Hemaglutininas/farmacologia , Receptores Tipo II do Fator de Necrose Tumoral/química , Choque Séptico/tratamento farmacológico , Choque Séptico/imunologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Fatores de Tempo
13.
Int Immunopharmacol ; 3(2): 267-72, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12586607

RESUMO

Sepsis remains an important and life-threatening problem, and is the most common cause of death in the intensive care unit. One promising therapeutic candidate for protection against injury in sepsis is fructose-1,6-bisphosphate (FBP), a high-energy glycolytic pathway intermediate. The objective of the study was to establish a role for FBP on the immune system, especially in lymphocyte proliferation. Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy humans by gradient centrifugation. T-lymphocytes were stimulated for 96 h with phytohemagglutinin (PHA) and varying concentration of FBP. Fructose-1,6-bisphosphate at concentrations between 1.2 and 10 mM decreased proliferation of T-lymphocytes and reduced the viability only at concentrations 5.0 and 10 mM. The levels of soluble IL-2 receptor were reduced at FBP concentrations between 1.2 and 10 mM. In conclusion, this study demonstrates that FBP has important effect on immunomodulatory and this result can be correlated with the protection against injury in sepsis.


Assuntos
Frutosedifosfatos/farmacologia , Imunossupressores/farmacologia , Ativação Linfocitária/efeitos dos fármacos , Linfócitos T/efeitos dos fármacos , Cálcio/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Humanos , Receptores de Interleucina-2/análise , Linfócitos T/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...